A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

This Phase 3 study is testing a new two-drug combination — IN10018 plus D-1553 — as a first-line treatment for people with advanced non-small cell lung cancer (NSCLC) that carries a specific genetic change called KRAS G12C. The combination is being compared to standard chemotherapy. **You may be eligible if...** - You are between 18 and 80 years old - You have been diagnosed with advanced or metastatic non-squamous NSCLC (stage IIIB/C or IV) - Your tumor has been confirmed to have the KRAS G12C mutation - You have not yet received any systemic treatment for advanced lung cancer - You have good overall health (ECOG performance status 0-1) and adequate organ function - You have at least one measurable tumor on imaging **You may NOT be eligible if...** - You have already received chemotherapy or targeted therapy for advanced NSCLC - Your cancer does not have the KRAS G12C mutation - You have significant health conditions that could affect your ability to tolerate treatment Talk to your doctor to see if this trial is right for you.